AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial
AstraZeneca's breast cancer pill Etcamah missed its primary goal in a late-stage trial, adding to oral SERD failures.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Recent coverage from Bloomberg.com, fiercepharma.com, STAT, AstraZeneca, and the Wall Street Journal reports that AstraZeneca's breast cancer drug, Etcamah, has missed its primary goal in a late-stage trial. Specifically, the Phase III clinical trial, known as SERENA-4, evaluated Etcamah in combination with palbociclib for upfront first-line advanced ER-positive breast cancer. The trial result establishes that the drug flunked this first-line breast cancer evaluation. Media outlets including fiercepharma.com and Bloomberg.com heavily emphasize the commercial and scientific implications of this trial outcome.
According to the reported coverage, this missed goal may trim billions from sales and adds to a broader failure record for oral selective estrogen receptor degraders, commonly known as oral SERDs. The company itself, AstraZeneca, released an update regarding the SERENA-4 Phase III trial of Etcamah in combination with palbociclib. This development arrives within the broader context of pharmaceutical research into oral SERDs, a class of therapies that has experienced notable setbacks in clinical evaluations. Coverage does not yet specify the exact numerical financial impact beyond noting the potential billions trimmed from sales, nor does it detail the exact alternative clinical pathways AstraZeneca plans to pursue for the compound following this pivotal trial miss.
Observers and market participants will be monitoring subsequent updates from AstraZeneca regarding the future development status of Etcamah. Coverage does not yet specify precise timelines for upcoming data presentations or regulatory decisions following the SERENA-4 trial outcome, leaving stakeholders to await further corporate announcements detailing the drug's next steps.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 65d ago.
Quick answers
Which company manufactures the breast cancer drug Etcamah?
AstraZeneca manufactures the drug.
What was the name of the late-stage trial that Etcamah missed its goal in?
The trial was the SERENA-4 Phase III trial.
What combination of drugs was evaluated in the SERENA-4 trial?
Etcamah was evaluated in combination with palbociclib.
Coverage (10)
- AZN Looks 11.6% Undervalued on GF Value™ GuruFocus · 65d ago
- Why is Olema Pharmaceuticals stock sliding today? By Investing.com Investing.com Nigeria · 65d ago
- AstraZeneca's breast cancer pill fails in late-stage trial Reuters · 65d ago
- Pharmalittle: We're reading about another AstraZeneca trial failure, a Novo name change, and more STAT · 65d ago
- AstraZeneca's oral SERD stumbles in Phase III first-line breast cancer trial FirstWord Pharma · 65d ago
- Astra Breast Cancer Pill Miss May Trim Billions From Sales Bloomberg.com · 65d ago
- AstraZeneca’s Etcamah flunks first-line breast cancer trial, adding to oral SERDs’ failure record fiercepharma.com · 65d ago
- Breast cancer pill from AstraZeneca misses mark in pivotal trial STAT · 65d ago
- Update on SERENA-4 Phase III trial of Etcamah in combination with palbociclib in upfront 1st-line advanced ER-positive breast cancer AstraZeneca · 65d ago
- AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial WSJ · 65d ago
Topics
Related trends
A cellular atlas of the preinvasive breast cancer microenvironment
A new single-cell atlas maps the microenvironment around preinvasive breast cancer, revealing cellular changes that may predict which cases progress to invasive disease.
The first pill to slow Alzheimer’s could come from an unexpected place
An experimental oral Alzheimer's drug derived from an unexpected medical category shows varied results in phase 3 clinical trials.
Roche Secures First U.S. Approval for New Breast-Cancer Pill
Roche wins FDA approval for its first U.S. oral SERD, giredestrant plus everolimus, for hormone-resistant advanced breast cancer.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.
Iowa ranks No. 2 for young adult cancer cases
Iowa ranks second nationally for young adult cancer cases as new research links rising rates to early detection of prostate and breast cancers while death rates decline.
New drug could be cure for common cause of high blood pressure
EU medicines panel recommends AstraZeneca's baxdrostat for uncontrolled hypertension, while new research suggests a potential cure for hormone-driven high blood pressure.